Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Sep 1;102(9):3296-3305.
doi: 10.1210/jc.2017-00992.

Malignant Pheochromocytoma and Paraganglioma: 272 Patients Over 55 Years

Oksana Hamidi  1 , William F Young Jr  1 , Nicole M Iñiguez-Ariza  1 , Nana Esi Kittah  1 , Lucinda Gruber  2 , Cristian Bancos  3 , Shrikant Tamhane  1 , Irina Bancos  1
Affiliations

Malignant Pheochromocytoma and Paraganglioma: 272 Patients Over 55 Years

Oksana Hamidi et al. J Clin Endocrinol Metab. .

Abstract

Context: Malignant pheochromocytoma (PHEO) and paraganglioma (PGL) are rare and knowledge of the natural history is limited.

Objective: We aimed to describe baseline characteristics and outcomes of patients with malignant PHEO and PGL (PPGL) and to identify predictors of shorter survival.

Design: Retrospective review of patients with malignant PPGL evaluated from 1960 to 2016.

Setting: Referral center.

Patients: The group comprised 272 patients.

Main outcome measures: Baseline description, survival outcomes, and predictors of shorter survival were evaluated in patients with rapidly progressive (n = 29) and indolent disease (n = 188).

Results: Malignant PPGL was diagnosed at a median age of 39 years (range, 7 to 83 years), with synchronous metastases in 96 (35%) patients. In 176 (65%) patients, metastases developed at a median of 5.5 years (range, 0.3 to 53.4 years) from the initial diagnosis. Median follow-up was 8.2 years (range, 0.01 to 54.1 years). Median overall and disease-specific survivals were 24.6 and 33.7 years, respectively. Shorter survival correlated with male sex (P = 0.014), older age at the time of primary tumor (P = 0.0011), synchronous metastases (P < 0.0001), larger primary tumor size (P = 0.0039), elevated dopamine (P = 0.0195), and not undergoing primary tumor resection (P < 0.0001). There was no difference in the type of primary tumor or presence of SDHB mutation.

Conclusions: The clinical course of patients with malignant PPGL is remarkably variable. Rapid disease progression is associated with male sex, older age at diagnosis, synchronous metastases, larger tumor size, elevated dopamine, and not undergoing resection of primary tumor. An individualized approach to patients with metastatic PPGL is warranted.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Outcomes of patients with malignant PPGL based on the duration of follow-up. Duration of follow-up was <1 year in 15 (6%) patients, 1 to 5 years in 69 (25%) patients, 5 to10 years in 66 (24%) patients, and >10 years in 122 (45%) patients.
Figure 2.
Figure 2.
Overall and disease-specific survival in patients with malignant PPGL. (a) Overall survival in patients with malignant PPGL. (b) Disease-specific survival in patients with malignant PPGL.
See this image and copyright information in PMC

References

    1. Beard CM, Sheps SG, Kurland LT, Carney JA, Lie JT. Occurrence of pheochromocytoma in Rochester, Minnesota, 1950 through 1979. Mayo Clin Proc. 1983;58(12):802–804. - PubMed
    1. Chen H, Sippel RS, O’Dorisio MS, Vinik AI, Lloyd RV, Pacak K; North American Neuroendocrine Tumor Society (NANETS) . The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer. Pancreas. 2010;39(6):775–783. - PMC - PubMed
    1. Amar L, Bertherat J, Baudin E, Ajzenberg C, Bressac-de Paillerets B, Chabre O, Chamontin B, Delemer B, Giraud S, Murat A, Niccoli-Sire P, Richard S, Rohmer V, Sadoul JL, Strompf L, Schlumberger M, Bertagna X, Plouin PF, Jeunemaitre X, Gimenez-Roqueplo AP. Genetic testing in pheochromocytoma or functional paraganglioma. J Clin Oncol. 2005;23(34):8812–8818. - PubMed
    1. Jimenez C, Rohren E, Habra MA, Rich T, Jimenez P, Ayala-Ramirez M, Baudin E. Current and future treatments for malignant pheochromocytoma and sympathetic paraganglioma. Curr Oncol Rep. 2013;15(4):356–371. - PubMed
    1. Dahia PL. Novel hereditary forms of pheochromocytomas and paragangliomas. Front Horm Res. 2013;41:79–91. - PubMed

Publication types

MeSH terms